Profound MedicalPROF -1.16%73 Receivables Turnover is 0.64 as of Mar. 2026. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 812 Medical Devices & Instruments companies, Profound Medical ranks worse than 86.21% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Profound Medical's Revenue for the
three
months ended in Mar. 2026 was $5.34 Mil. Profound Medical's average Accounts Receivable for the
three
months ended in Mar. 2026 was $8.31 Mil.
Hence, Profound Medical's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.64.
Profound Medical (NAS:PROF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Profound Medical Receivables Turnover Related Terms
Profound Medical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Profound Medical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROF vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Profound Medical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Profound Medical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a Receivables Turnover of 0.64 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #700 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 86.2%.
Is Profound Medical's Receivables Turnover too high?
Profound Medical's current Receivables Turnover is 0.64. The Medical Devices & Instruments industry median Receivables Turnover is 5.53. Profound Medical's value of 0.64 is 88.4% below this industry median. Based on the distribution chart, Profound Medical ranks #700 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #700 out of 812 companies for Receivables Turnover. This places Profound Medical in the lower half of its industry. The industry median Receivables Turnover is 5.53. Profound Medical's value of 0.64 is 88.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.53, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Receivables Turnover of 0.64 is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Receivables Turnover is 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.25 — trading 49.2% below its estimated fair value. The current Receivables Turnover is 0.64 and 88.4% below the Medical Devices & Instruments industry median of 5.53. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Profound Medical (PROF), the current Receivables Turnover is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.25 is trading 49.2% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Receivables Turnover: 0.64
GF Value™: $14.28 vs. price of $7.25 (49.2% below fair value)
Industry Position: 88.4% below the Medical Devices & Instruments median (#700 of 812)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
